Aims and scope

Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.

Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.

Featured research article: Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia: a population-based cohort study

In this population-based cohort study, Yen-Chun Fan and colleagues investigated how dementia risk is affected by hypertension, hyperlipidemia and dementia mellitus. Across 51,580 patients, dementia risk was not significantly higher in those with either hypertension, hyperlipidemia or a combination of the two. However, the dementia risk in all patients with diabetes mellitus was significantly higher than that in patients without diabetes mellitus. This suggests that diabetes mellitus itself, not conditions related to it, may be drive increased dementia risk.


Read more

Featured review: An update on semantic dementia: genetics, imaging, and pathology

In this review from Landin-Romero et al., they review recent neuroimaging, pathological and genetic research into semantic dementia. They conclude that the pathological homogeneity, clear diagnosis and clinical course make this syndrome a promising target for new interventions. To assist with this, they recommend emphasising the development of neuroimaging disease progression markers.


Read more

Editors-in-Chief

Alzheimer's Research & Therapy is edited by Philip Scheltens, Todd Golde and Doug Galasko. Find the full Editorial Board here.

Articles

View all articles

View all articles

Alzheimer's Disease International news



The 32nd International Conference of Alzheimer's Disease International will take place on 26-29 April 2017. The conference is one of the world’s largest and most important conferences on Alzheimer’s disease and dementia, featuring a range of international keynote speakers and a high standard of scientific and non-scientific content; combined, this makes it the optimum setting to learn about the latest advances in the treatment of dementia.

The Early Bird registration deadline is 19 February 2017. Register today

Featured collection: Lewy Body Dementia


Edited by Ian McKeith and James Galvin, this special series takes a translational view of Lewy body dementia from bedside to bench and back. Visit our collections page to find our full list of special series, including thematic series on Innate immunity and Traumatic brain injury.

Advertisement

Advertisement